. Author manuscript; available in PMC: 2024 Mar 27.

Published in final edited form as: Curr Treat Options Gastroenterol. 2020 Jan 21;18(1):109–119. doi: 10.1007/s11938-020-00271-5

Table 2.

Screening with multi-target stool DNA testing results in fewer lifetime colonoscopies than FIT, and has a superior benefit-to-harm ratio compared to colonoscopy

Screening Modality	Life years gained^*	CRC deaths averted^*	Complications (GI/CV)^*	Colonoscopies^*	Life years gained/complication	Life years gained/colonoscopy	CRC deaths averted/complication	CRC deaths averted colonoscopy
MT-sDNA	226	20	9	1714	25	0.13	2.2	0.01
FIT	244	22	10	1757	24	0.14	2.2	0.01
Colonoscopy	270	24	15	4049	18	0.07	1.6	0.006

Adapted from: Bibbens-Domingo, et al. [3]

Per 1000 persons screened